Publicaciones (45) Publicaciones de ANA LOIZAGA IRIARTE

2024

  1. MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics

    Cardiovascular Diabetology, Vol. 23, Núm. 1

  2. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. Identifying prognostic parameters related to surgical technique in patients treated by robotic radical prostatectomy

    Actas Urologicas Espanolas, Vol. 47, Núm. 1, pp. 47-55

  2. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

    Molecular cancer, Vol. 22, Núm. 1, pp. 119

2022

  1. PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer

    Oncogenesis, Vol. 11, Núm. 1

2021

  1. Clinical implications of (Pro)renin receptor (prr) expression in renal tumours

    Diagnostics, Vol. 11, Núm. 2

  2. Soluble pd-l1 is an independent prognostic factor in clear cell renal cell carcinoma

    Cancers, Vol. 13, Núm. 4, pp. 1-17

2020

  1. 1H NMR-Based Urine Metabolomics Reveals Signs of Enhanced Carbon and Nitrogen Recycling in Prostate Cancer

    Journal of Proteome Research, Vol. 19, Núm. 6, pp. 2419-2428

  2. Perspectiva histórica del tratamiento sistémico del cáncer de vejiga músculo invasivo

    Archivos espanoles de urologia, Vol. 73, Núm. 10, pp. 954-960

  3. The urinary transcriptome as a source of biomarkers for prostate cancer

    Cancers, Vol. 12, Núm. 2

2018

  1. Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer

    Cell Death and Disease, Vol. 9, Núm. 10

  2. Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression

    Journal of Extracellular Vesicles, Vol. 7, Núm. 1

  3. PPARd elicits ligand-independent repression of trefoil factor family to limit prostate cancer growth

    Cancer Research, Vol. 78, Núm. 2, pp. 399-409

  4. Radio 223 en cáncer de próstata resistente a la castración

    Archivos espanoles de urologia, Vol. 71, Núm. 8, pp. 696-703

2017

  1. Cáncer de próstata resistente a la castración. Recomendaciones de consenso de la Asociación Española de Urología

    Actas Urologicas Espanolas

  2. MTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

    Nature, Vol. 547, Núm. 7661, pp. 109-113

2016

  1. Comparative miRNA analysis of urine extracellular vesicles isolated through five different methods

    Cancers, Vol. 8, Núm. 12

  2. Different EV enrichment methods suitable for clinical settings yield different subpopulations of urinary extracellular vesicles from human samples

    Journal of Extracellular Vesicles, Vol. 5, Núm. 1

  3. The metabolic co-regulator PGC1α suppresses prostate cancer metastasis

    Nature Cell Biology, Vol. 18, Núm. 6, pp. 645-656

  4. Vesicle-MaNiA: Extracellular vesicles in liquid biopsy and cancer

    Current Opinion in Pharmacology, Vol. 29, pp. 47-53